Elias Jabbour

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 102 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature Medicine(2023)10.1038/s41591-022-02103-8

N/A

4.3DataRank · unranked

388 citations

Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka, Funda Meric‐Bernstam +44 more

Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017

American Journal of Hematology(2021)10.1002/ajh.26156

N/A

3.3DataRank · unranked

131 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Farhad Ravandi, Ching‐Hon Pui +2 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood(2021)10.1182/blood.2021013290

N/A

2.6DataRank · unranked

87 citations

Pinaki P. Banerjee, Denái R. Milton, Xianli Jiang, Christina Ganesh, Sajad Khazal +24 more

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001156

N/A

2.1DataRank · unranked

43 citations

Keyur P. Patel, Maher Albitar, Miguel Franquiz, Rajyalakshmi Luthra, Rashmi Kanagal‐Shamanna +15 more

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26238

N/A

1.8DataRank · unranked

55 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Naval Daver, Tapan M. Kadia +8 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

1.6DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

1.4DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Blood Cancer Journal(2020)10.1038/s41408-020-0329-y

N/A

1.1DataRank · unranked

36 citations

Hagop M. Kantarjian, Rashmi Kanagal‐Shamanna, Koji Sasaki, Farhad Ravandi, Jörge E. Cortes +15 more

Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study

American Journal of Hematology(2021)10.1002/ajh.26281

N/A

0.952DataRank · unranked

32 citations

Keyur P. Patel, Nitin Jain, Dzifa Y. Duose, Rajyalakshmi Luthra, Nicholas J. Short +8 more

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0.776DataRank · unranked

176 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0.735DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0.728DataRank · unranked

127 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0.717DataRank · unranked

118 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0.697DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0.692DataRank · unranked

100 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

The cure of leukemia through the optimist's prism

Cancer(2021)10.1002/cncr.33933

N/A

0.633DataRank · unranked

67 citations

Nitin Jain, Guillermo Garcia‐Manero, Mary Alma Welch, Farhad Ravandi, William G. Wierda +2 more

Clonal Evolution of Acute Myeloid Leukemia Revealed by High-Throughput Single-Cell Genomics

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.02.07.925743

N/A

0.633DataRank · unranked

67 citations

Feng Wang, Katharina Jahn, Jack Kuipers, Yuanqing Yan, Jairo Matthews +22 more

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia

Nature Communications(2022)10.1038/s41467-022-30396-3

N/A

0.624DataRank · unranked

63 citations

Alessia Lodi, Yogesh Dhungana, Shelley M. Herbrich, Meghan Collins, Shannon Sweeney +50 more

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia

Haematologica(2020)10.3324/haematol.2020.256453

N/A

0.614DataRank · unranked

9 citations

Ronald M. Paranal, Jabra Zarka, Shilpa Paul, Koji Sasaki, Wen Li +7 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0.606DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Blood(2022)10.1182/blood.2022015444

N/A

0.596DataRank · unranked

52 citations

Lindsey E. Montefiori, Ilaria Iacobucci, Yaqi Zhao, Qingsong Gao, Elisabeth Paietta +31 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0.596DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0.593DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0.593DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial

The Lancet Haematology(2024)10.1016/s2352-3026(24)00250-3

N/A

0.561DataRank · unranked

17 citations

Daniel Nguyen, Elias Jabbour, Jayastu Senapati, Zhihong Zeng, Ghayas C. Issa +14 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0.547DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

American Journal of Hematology(2021)10.1002/ajh.26417

N/A

0.546DataRank · unranked

37 citations

Marina Konopleva, Mrinal M. Patnaik, Elias Jabbour, Courtney D. DiNardo, Aref Al‐Kali +7 more

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01106-1

N/A

0.546DataRank · unranked

37 citations

Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti +11 more

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Cancer Cell(2024)10.1016/j.ccell.2024.03.003

N/A

0.542DataRank · unranked

36 citations

Yizhen Li, Jingliao Zhang, Lei Yan, Huanbin Zhao, Liang Ding +21 more

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Blood Advances(2025)10.1182/bloodadvances.2024015441

N/A

0.533DataRank · unranked

34 citations

Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica Leonard, Aaron C. Logan +5 more

Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019

Cancer(2023)10.1002/cncr.35038

N/A

0.529DataRank · unranked

33 citations

Fadi Haddad, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Elias Jabbour +2 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0.524DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0.524DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0.520DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0.510DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0.489DataRank · unranked

25 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.016

N/A

0.483DataRank · unranked

24 citations

Elias Jabbour, Trevor Jamison, Shilpa Paul, Branko Cuglievan, David McCall +11 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0.483DataRank · unranked

24 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0.483DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0.464DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Journal of Hematology & Oncology(2024)10.1186/s13045-024-01552-7

N/A

0.457DataRank · unranked

20 citations

Elias Jabbour, Nitin B. Jain, Hagop M. Kantarjian, Nicholas J. Short

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037

N/A

0.457DataRank · unranked

20 citations

Koji Sasaki, Aram Bidikian, Ghayas C. Issa, Tapan M. Kadia, Nitin Jain +11 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0.457DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0.457DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia

Journal of Clinical Oncology(2024)10.1200/jco.24.00500

N/A

0.442DataRank · unranked

18 citations

Zhenhua Li, Yoshihiro Gocho, Wenjian Yang, Kristine R. Crews, Shawn H.R. Lee +21 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0.442DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic–Resistant AML and AML Stem Cells

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0690

N/A

0.425DataRank · unranked

16 citations

Po Yee Mak, Wenjing Tao, Qi Zhang, Vivian Ruvolo, Vinitha M. Kuruvilla +10 more

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0.416DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0.360DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0.360DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Bone Marrow Transplantation(2023)10.1038/s41409-023-02006-3

N/A

0.345DataRank · unranked

9 citations

Yingjun Wang, Denái R. Milton, Zijun Y. Xu‐Monette, Elias Jabbour, May Daher +13 more

A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.05.013

N/A

0.344DataRank · unranked

8 citations

Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Naveen Pemmaraju, Koichi Takahashi +4 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0.330DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin

Blood(2025)10.1182/blood.2024028215

N/A

0.312DataRank · unranked

7 citations

Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Satoshi Yoshimura +16 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0.312DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1377

N/A

0.312DataRank · unranked

7 citations

Denái R. Milton, Alison Gulbis, Elias Jabbour, Loretta J. Nastoupil, Celina Ledesma +16 more

Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2021)10.1038/s41467-021-23280-z

N/A

0.312DataRank · unranked

7 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission

Transplantation and Cellular Therapy(2024)10.1016/j.jtct.2024.09.020

N/A

0.312DataRank · unranked

7 citations

Tamer Othman, Rima M. Saliba, Yenny Alejandra Moreno Vanegas, Razan Mohty, Celina Ledesma +18 more

Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial

American Journal of Hematology(2024)10.1002/ajh.27254

N/A

0.269DataRank · unranked

5 citations

Kamal Alzahrani, Hagop M. Kantarjian, Denái R. Milton, Alison Gulbis, Koji Sasaki +18 more

Targeting Oxidative Phosphorylation with a Mitochondrial Complex I Inhibitor is limited by Mechanism-based Toxicity

Research Square(2022)10.21203/rs.3.rs-1506700/v1

N/A

0.269DataRank · unranked

5 citations

Timothy A. Yap, Naval Daver, Mikhila Mahendra, Jixiang Zhang, Carlos Kamiya-Matsuoka +43 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia

Blood Cancer Discovery(2026)10.1158/2643-3230.bcd-25-0264

N/A

0.208DataRank · unranked

3 citations

Chong Wu, Juan José Rodríguez‐Sevilla, Yue Wei, Kelly S. Chien, Ian Bouligny +36 more

Epigenomic mapping in B-cell acute lymphoblastic leukemia identifies transcriptional regulators and noncoding variants promoting distinct chromatin architectures

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.14.528493

N/A

0.208DataRank · unranked

3 citations

Robert J. Mobley, Jonathan D. Diedrich, Brennan P. Bergeron, Kashi Raj Bhattarai, Wenjian Yang +16 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565

N/A

0.208DataRank · unranked

3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0.182DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0.165DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0.165DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

medRxiv(2023)10.1101/2023.12.06.23299616

N/A

0.132DataRank · unranked

1 citations

Nicholas J. Short, Hagop M. Kantarjian, Ti‐Cheng Chang, Pankaj S. Ghate, Chunxu Qu +17 more

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study

Leukemia Research(2024)10.1016/j.leukres.2024.107597

N/A

0.104DataRank · unranked

1 citations

Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa Ghayas, Ravin Ratan +3 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0.104DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0.104DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0.104DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

Functional investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment

medRxiv(2023)10.1101/2023.02.10.23285762

N/A

0DataRank · unranked

0 citations

Robert J. Mobley, Kelly R. Barnett, Daniel C. Ferguson, Baranda S. Hansen, Jonathan D. Diedrich +19 more

Inferior Outcomes in Acute Lymphoblastic Leukemia With Translocation (14;18)

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.03.010

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Álex Bataller, Koji Sasaki, Guilin Tang, Sanam Loghavi +7 more

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy‐Based Regimens

American Journal of Hematology(2025)10.1002/ajh.70048

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Himachandana Atluri +9 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring

American Journal of Hematology(2025)10.1002/ajh.27708

N/A

0DataRank · unranked

48 citations

Elias Jabbour, Hagop M. Kantarjian

Management of chronic myeloid leukemia in 2025

Cancer(2025)10.1002/cncr.35953

N/A

0DataRank · unranked

37 citations

Massimo Breccia, Fadi Haddad, Rüdiger Hehlmann, Ghayas C. Issa, Hemant Malhotra +5 more

Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Nature Communications(2020)10.1038/s41467-020-19119-8

N/A

0DataRank · unranked

391 citations

Feng Wang, Katharina Jahn, Tianyuan Hu, Tomoyuki Tanaka, Yuya Sasaki +28 more

Acute lymphocytic leukaemia

The Lancet(2025)10.1016/s0140-6736(25)00864-5

N/A

0DataRank · unranked

30 citations

Ching‐Hon Pui, Elias Jabbour, Hagop Kantarjian

Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators

Cell Genomics(2023)10.1016/j.xgen.2023.100442

N/A

0DataRank · unranked

16 citations

Robert J. Mobley, Jonathan D. Diedrich, Brennan P. Bergeron, Kashi Raj Bhattarai, Alexander C. Monovich +20 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia

Nature Cancer(2021)10.1038/s43018-020-00167-4

N/A

0DataRank · unranked

159 citations

Jingjing Liu, Jianzhong Hu, Wentao Yang, Neekesh V. Dharia, Jingliao Zhang +42 more

The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis

Blood(2022)10.1182/blood.2022016194

N/A

0DataRank · unranked

88 citations

Michael Slade, Hagop M. Kantarjian, Julio Alvarenga, Ibrahim Aldoss, Kahee A. Mohammed +16 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia

Blood Cancer Journal(2022)10.1038/s41408-022-00742-1

N/A

0DataRank · unranked

51 citations

Hagop M. Kantarjian, Elias Jabbour, Nicholas J. Short, Keyur P. Patel, Farhad Ravandi +3 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

1250MO Outcomes of patients with chronic myeloid leukemia receiving second-line therapy

Annals of Oncology(2025)10.1016/j.annonc.2025.08.1884

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Sara Dellasala, G. Issa, Tapan Kadia, J. Senapati +10 more

Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment

Nature Communications(2024)10.1038/s41467-024-48124-4

N/A

0DataRank · unranked

8 citations

Robert J. Mobley, Kelly R. Barnett, Daniel C. Ferguson, Baranda S. Hansen, Jonathan D. Diedrich +20 more

Germline DNMT3A mutation in familial acute myeloid leukaemia

Epigenetics(2020)10.1080/15592294.2020.1809871

N/A

0DataRank · unranked

10 citations

Hannah C. Beird, Marcos R. Estecio, Swanand Hardikar, Koichi Takahashi, Sarah A. Bannon +12 more

Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.003

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Jayastu Senapati, Shimin Hu, Sara Dellasala, Ghayas C. Issa +3 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more